Live from ASH: Updates on the Treatment of Multiple Myeloma

Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 5 de diciembre del 2008

Share article


Imprima English

Guest: Dan Vogl, M.D.
Date: Monday, December 8, 2008
Time: 10:00 – 10:30 am Pacific
Where to Listen: www.patientpower.info

Email questions in advance or during the live show to: Questions@patientpower.info

Imprima English
News
ASH: Novel Drug Beneficial in Multiple Myeloma

Jul 30, 2014 - In patients with relapsed or resistant multiple myeloma who have received up to three prior therapies excluding the first-generation proteasome inhibitor bortezomib, treatment with the second-generation proteasome inhibitor carfilzomib is associated a high response rate and a low incidence of side effects, according to research presented at the annual meeting of the American Society of Hematology, held from Dec. 5 to 8 in New Orleans.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información